Thomas J Vogl1, Patrik Schaefer2, Thomas Lehnert2, Nour-Eldin A Nour-Eldin2,3, Hanns Ackermann4, Emmanuel Mbalisike2, Renate Hammerstingl2, Katrin Eichler2, Stephan Zangos2, Nagy N N Naguib2,5. 1. Institute for Diagnostic and Interventional Radiology, Johann Wolfgang Goethe-University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany. T.Vogl@em.uni-frankfurt.de. 2. Institute for Diagnostic and Interventional Radiology, Johann Wolfgang Goethe-University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany. 3. Department of Radiology, Faculty of Medicine (Kasr Al-Ainy), Cairo University, Cairo, Egypt. 4. Department of Biomedical Statistics, Johann Wolfgang Goethe-University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany. 5. Department of Radiology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Abstract
PURPOSE: To evaluate feasibility of measuring parenchymal blood volume (PBV) of malignant hepatic tumours using C-arm CT, test the changes in PBV following repeated transarterial chemoembolization (TACE) and correlate these changes with the change in tumour size in MRI. METHODS: 111 patients with liver malignancy were included. Patients underwent MRI and TACE in a 4- to 6-week interval. During intervention C-arm CT was performed. Images were post-processed to generate PBV maps. Blood volume data in C-arm CT and change in size in MRI were evaluated. The correlation between PBV and size was tested using Spearman rank test. RESULTS: Pre-interventional PBV maps showed a mean blood volume of 84.5 ml/1000 ml ± 62.0, follow-up PBV maps after multiple TACE demonstrated 61.1 ml/1000 ml ± 57.5. The change in PBV was statistically significant (p = 0.02). Patients with initial tumour blood volume >100 ml/1000 ml dropped 7.1% in size and 47.2% in blood volume; 50-100 ml/1000 ml dropped 4.6% in size and 25.7% in blood volume; and <50 ml/1000 ml decreased 2.8% in size and increased 82.2% in blood volume. CONCLUSION: PBV measurement of malignant liver tumours using C-arm CT is feasible. Following TACE PBV decreased significantly. Patients with low initial PBV show low local response rates and further increase in blood volume, whereas high initial tumour PBV showed better response to TACE. KEY POINTS: Parenchymal blood volume assessment of malignant hepatic lesions using C-arm CT is feasible. The parenchymal blood volume is reduced significantly following transarterial chemoembolization. Parenchymal blood volume can monitor the response of tumours after transarterial chemoembolization. Although not significant, high initial parenchymal blood volume yields better response to TACE.
PURPOSE: To evaluate feasibility of measuring parenchymal blood volume (PBV) of malignant hepatic tumours using C-arm CT, test the changes in PBV following repeated transarterial chemoembolization (TACE) and correlate these changes with the change in tumour size in MRI. METHODS: 111 patients with liver malignancy were included. Patients underwent MRI and TACE in a 4- to 6-week interval. During intervention C-arm CT was performed. Images were post-processed to generate PBV maps. Blood volume data in C-arm CT and change in size in MRI were evaluated. The correlation between PBV and size was tested using Spearman rank test. RESULTS: Pre-interventional PBV maps showed a mean blood volume of 84.5 ml/1000 ml ± 62.0, follow-up PBV maps after multiple TACE demonstrated 61.1 ml/1000 ml ± 57.5. The change in PBV was statistically significant (p = 0.02). Patients with initial tumour blood volume >100 ml/1000 ml dropped 7.1% in size and 47.2% in blood volume; 50-100 ml/1000 ml dropped 4.6% in size and 25.7% in blood volume; and <50 ml/1000 ml decreased 2.8% in size and increased 82.2% in blood volume. CONCLUSION:PBV measurement of malignant liver tumours using C-arm CT is feasible. Following TACE PBV decreased significantly. Patients with low initial PBV show low local response rates and further increase in blood volume, whereas high initial tumourPBV showed better response to TACE. KEY POINTS: Parenchymal blood volume assessment of malignant hepatic lesions using C-arm CT is feasible. The parenchymal blood volume is reduced significantly following transarterial chemoembolization. Parenchymal blood volume can monitor the response of tumours after transarterial chemoembolization. Although not significant, high initial parenchymal blood volume yields better response to TACE.
Authors: H K Kim; Y H Chung; B C Song; S H Yang; H K Yoon; E Yu; K B Sung; Y S Lee; S G Lee; D J Suh Journal: J Clin Gastroenterol Date: 2001 May-Jun Impact factor: 3.062
Authors: Seung Hong Choi; Jin Wook Chung; Hyo-Cheol Kim; Hyo-Choel Kim; Jin Ho Baek; Chang Min Park; Suryoung Jun; Min Uk Kim; Eun Sun Lee; Hye Rim Cho; Hwan Jun Jae; Whal Lee; Jae Hyung Park Journal: Invest Radiol Date: 2010-07 Impact factor: 6.016
Authors: Thomas J Vogl; Nagy N N Naguib; Nour-Eldin A Nour-Eldin; Martin G Mack; Stefan Zangos; John E Abskharon; Alexandra Jost Journal: AJR Am J Roentgenol Date: 2011-01 Impact factor: 3.959
Authors: H J Jaeger; U M Mehring; F Castañeda; F Hasse; G Blumhardt; D Loehlein; K D Mathias Journal: Cardiovasc Intervent Radiol Date: 1996 Nov-Dec Impact factor: 2.740
Authors: Michael B Pitton; Roman Kloeckner; Christian Ruckes; Gesine M Wirth; Waltraud Eichhorn; Marcus A Wörns; Arndt Weinmann; Mathias Schreckenberger; Peter R Galle; Gerd Otto; Christoph Dueber Journal: Cardiovasc Intervent Radiol Date: 2014-11-07 Impact factor: 2.740
Authors: Pierleone Lucatelli; Gianluca De Rubeis; Fabrizio Basilico; Luca Ginanni Corradini; Mario Corona; Mario Bezzi; Carlo Catalano Journal: Radiol Med Date: 2019-08-31 Impact factor: 3.469
Authors: Roland Syha; Gerd Grözinger; Ulrich Grosse; Michael Maurer; Lars Zender; Marius Horger; Konstantin Nikolaou; Dominik Ketelsen Journal: Cancer Imaging Date: 2015-12-29 Impact factor: 3.909
Authors: Christina Schraml; Sascha Kaufmann; Hansjoerg Rempp; Roland Syha; Dominik Ketelsen; Mike Notohamiprodjo; Konstantin Nikolaou Journal: Diagnostics (Basel) Date: 2015-11-27
Authors: Roland Syha; Sergios Gatidis; Gerd Grözinger; Ulrich Grosse; Michael Maurer; Lars Zender; Marius Horger; Konstantin Nikolaou; Dominik Ketelsen Journal: Cancer Imaging Date: 2016-09-21 Impact factor: 3.909